|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-12-2
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in vitro. The week 96 analysis of TMC278-C204, a large dose-ranging study of TMC278 in treatment-naive HIV-1-infected patients, is presented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
pubmed-author:BovenKatiaK,
pubmed-author:GrinsztejnBeatrizB,
pubmed-author:KatabiraEllyE,
pubmed-author:LupoSergio HSH,
pubmed-author:Morales-RamirezJavierJ,
pubmed-author:PozniakAnton LAL,
pubmed-author:RimskyLaurence TLT,
pubmed-author:RuxrungthamKiatK,
pubmed-author:SantoscoyMarioM,
pubmed-author:SteynDewaldD,
pubmed-author:TMC278-C204 Study Group,
pubmed-author:VanveggelSimonS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
2
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
55-65
|
|
pubmed:meshHeading |
pubmed-meshheading:19926964-Adult,
pubmed-meshheading:19926964-Aged,
pubmed-meshheading:19926964-Anti-HIV Agents,
pubmed-meshheading:19926964-Dose-Response Relationship, Drug,
pubmed-meshheading:19926964-Drug Resistance, Viral,
pubmed-meshheading:19926964-Female,
pubmed-meshheading:19926964-HIV Infections,
pubmed-meshheading:19926964-HIV Reverse Transcriptase,
pubmed-meshheading:19926964-HIV-1,
pubmed-meshheading:19926964-Humans,
pubmed-meshheading:19926964-Male,
pubmed-meshheading:19926964-Middle Aged,
pubmed-meshheading:19926964-Nitriles,
pubmed-meshheading:19926964-Pyrimidines,
pubmed-meshheading:19926964-Reverse Transcriptase Inhibitors,
pubmed-meshheading:19926964-Treatment Outcome,
pubmed-meshheading:19926964-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
|
|
pubmed:affiliation |
Chelsea and Westminster NHS Foundation Trust and PKR/SSR, London, UK. anton.pozniak@chelwest.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
